ストックスクリーナーアプリを入手
9.70
3.41%
0.32
アフターアワーズ：
9.70
前日終値:
$9.38
開ける：
$9.46
24時間の取引高:
27,085
Relative Volume:
0.34
時価総額：
$97.37M
収益：
$23.14M
当期純損益:
$-9.47M
株価収益率:
-10.99
EPS:
-0.8827
ネットキャッシュフロー:
$-25.88M
1週間 パフォーマンス:
+19.90%
1か月 パフォーマンス:
+12.40%
6か月 パフォーマンス:
+132.06%
1年 パフォーマンス:
-15.58%
1日の値動き範囲:
$9.15
$9.89
1週間の範囲:
$7.81
$9.89
52週間の値動き範囲:
$3.92
$19.14
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
名前
Atara Biotherapeutics Inc
セクター
電話
805-623-4211
住所
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Compare ATRA vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
9.70 | 94.15M | 23.14M | -9.47M | -25.88M | -0.8827 |
VRTX
Vertex Pharmaceuticals Inc
|
548.05 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
834.04 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,039.78 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.13 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.46 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-13 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2023-11-09 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2023-11-09 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-11-09 | ダウングレード | Mizuho | Buy → Neutral |
| 2022-07-20 | ダウングレード | Citigroup | Neutral → Sell |
| 2022-07-13 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-07-13 | ダウングレード | Stifel | Buy → Hold |
| 2022-05-10 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-05-13 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-12-09 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-12-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-11-10 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-06-30 | 開始されました | Evercore ISI | Outperform |
| 2020-06-15 | 開始されました | H.C. Wainwright | Buy |
| 2020-04-23 | アップグレード | Citigroup | Neutral → Buy |
| 2019-11-08 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-09-27 | ダウングレード | Goldman | Neutral → Sell |
| 2019-09-16 | ダウングレード | Jefferies | Buy → Hold |
| 2019-06-04 | アップグレード | Citigroup | Sell → Neutral |
| 2019-05-30 | 開始されました | ROTH Capital | Buy |
| 2019-05-23 | 開始されました | Stifel | Buy |
| 2019-01-23 | 開始されました | Mizuho | Buy |
| 2018-04-10 | 開始されました | JP Morgan | Overweight |
| 2018-03-16 | 開始されました | Guggenheim | Neutral |
| 2018-03-05 | 繰り返されました | Jefferies | Buy |
| 2018-02-28 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-02-15 | ダウングレード | Citigroup | Neutral → Sell |
| 2018-01-03 | アップグレード | Citigroup | Sell → Neutral |
| 2017-10-06 | 再開されました | Goldman | Neutral |
すべてを表示
Atara Biotherapeutics Inc (ATRA) 最新ニュース
Atara (ATRA) Results Breakdown: Profit Per Share Surpasses Its Benchmark on the Day; Post-Report Move: The Stock Records a 1.26% Increase at the CloseProfit Growth Outlook - Vinanet
ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Atara Biotherapeutics (NASDAQ:ATRA) Rating Increased to Hold at Wall Street Zen - MarketBeat
Why (ATRA) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Atara Biotherapeutics (ATRA): Point72 entities report 7.6% beneficial stake - Stock Titan
Atara Biotherapeutics, Inc.: Revenue and Earnings Analysts Forecasts Revisions | ATRA | US0465132068 - marketscreener.com
Atara Biotherapeutics Inc earnings missed by $0.10, revenue fell short of estimates - Investing.com Nigeria
Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress - BioSpace
Atara Biotherapeutics cuts costs 87%, extends cash runway to mid-2027 - scanx.trade
Is Atara Biotherapeutics Inc (ATRA) Positioned for Growth After - GuruFocus
Atara Biotherapeutics (NASDAQ:ATRA) Announces Quarterly Earnings Results - MarketBeat
Atara Biotherapeutics 2Q 2026: Revenue $0.63M, Net loss $(9.0)M — 10-Q Summary - TradingView
Atara Biotherapeutics: Q2 Earnings Snapshot - AOL.com
BRIEF-Atara Biotherapeutics Q2 EPS USD -0.32 - TradingView
Atara Biotherapeutics (ATRA) Rallies 3.8% to $8.94, Approaching Resistance at $9.39Negative Gamma - Vinanet
Atara Biotherapeutics (NASDAQ:ATRA): What Could Today’s Update Reveal About Program Focus And Funding Discipline? - Kalkine Media
ATRA DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Reminds - The National Law Review
Atara Biotherapeutics (NASDAQ:ATRA) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
Atara Biotherapeutics Inc (ATRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Atara Biotherapeutics, Inc. expected to post a loss of 31 cents a shareEarnings Preview - TradingView
ATRA Q2'26 Earnings: EPS estimate is (0.32) USD - TradingView
ATRA DEADLINEFINAL REMINDER: Bronstein, Gewirtz & Grossman LLC - The National Law Review
Understanding Momentum Shifts in (ATRA) - Stock Traders Daily
ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
ATRA Q2'26 Earnings: revenue estimate is 550.00K USD - TradingView
Atara Biotherapeutics (ATRA) Projected to Release Earnings on Monday - MarketBeat
Enterprise value to revenue forward of Atara Biotherapeutics, Inc. – NASDAQ:ATRA - TradingView
Atara Biotherapeutics Inc (ATRA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
EcoR1 Capital LLC Sells 473,590 Shares of Atara Biotherapeutics, Inc. $ATRA - MarketBeat
Atara Biotherapeutics Inc (ATRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Atara Biotherapeutics Inc (ATRA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Atara Biotherapeutics Inc (ATRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Atara Biotherapeutics Inc (ATRA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
Form 13D/A Atara Biotherapeutics For: 24 July By Investing.com - Investing.com South Africa
Atara Biotherapeutics Inc (ATRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Form 4 Atara Biotherapeutics Inc For: 24 July By Investing.com - Investing.com South Africa
Atara Biotherapeutics, Inc. Revenue Breakdown – NASDAQ:ATRA - TradingView
Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Shareholders to Connect - ACCESS Newswire
Redmile adjusts Atara Biotherapeutics (ATRA) ownership after warrant exercises - Stock Titan
ATRA|Atara Biotherapeutics Inc|Price:7.559|Chg%:-0.151 - TradingKey
Atara Biotherapeutics Inc (ATRA) Cash Flow - TradingKey
Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Price to book forward of Atara Biotherapeutics, Inc. – NASDAQ:ATRA - TradingView
Avoiding Lag: Real-Time Signals in (ATRA) Movement - Stock Traders Daily
Atara Biotherapeutics (NASDAQ:ATRA) Share Price Passes Below 50-Day Moving AverageShould You Sell? - MarketBeat
Price to sales forward of Atara Biotherapeutics Inc – SWB:AT20 - TradingView
Price to book forward of Atara Biotherapeutics Inc – SWB:AT20 - TradingView
Enterprise value to revenue forward of Atara Biotherapeutics Inc – SWB:AT20 - TradingView
Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect - ACCESS Newswire
Atara Biotherapeutics Inc (ATRA) 財務データ
収益
当期純利益
現金流量
EPS
1.21%
1.07%
大文字化:
|
ボリューム (24 時間):